Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jun;39(3):e22134.
doi: 10.1002/jca.22134.

Therapeutic plasmapheresis in idiopathic membranous nephropathy anti-PLA2R-related: A case series

Dario Musone  1 , Valentina Nicosia  1 , Riccardo D'Alessandro  1 , Marco Andrietti  1 , Paolo Francesco Steri  1 , Carolina Ruosi  1 , Sofia Giuliana  1 , Claudia Elefante  1 , Pina Cuccurullo  1 , Antonio Treglia  1
Affiliations
Case Reports

Therapeutic plasmapheresis in idiopathic membranous nephropathy anti-PLA2R-related: A case series

Dario Musone et al. J Clin Apher. 2024 Jun.

Abstract

Membranous nephropathy is the most common cause of nephrotic syndrome (NS) in non-diabetic adults; in 80% of patients it is idiopathic (PMN). PMN has an autoimmune pathogenesis, 70%-85% of patients have increased titer of antibodies to the podocyte membrane antigen PLA2R. The etiological, prognostic and predictive role of the Ab anti-PLA2R is demonstrated. Standard therapy consists in anti-CD20 monoclonal antibody rituximab (RTX) combined with steroids or immunosuppressants according to the risk of progressive loss of kidney function. The immunosuppressive therapies are potentially associated to severe adverse events that lead to protocol suspension. Given their pivotal pathogenetic role, serum clearance of anti-PLA2R with plasmapheresis could have a beneficial impact on NS, particularly in patients not requiring or tolerating standard therapies. In this series, we present three cases of PMN anti-PLA2R related treated with a RTX plus plasmapheresis approach and demonstrate its overall effective role on anti-PLA2R titer and clinical outcomes.

Keywords: anti‐PLA2R; membranous nephropathy; nephrotic syndrome; plasmapheresis.

PubMed Disclaimer

References

REFERENCES

    1. Bomback A, Fervenza FC. Membranous nephropathy: approaches to treatment. Am J Nephrol. 2018;47(Suppl 1):30‐42.
    1. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry Group: idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66:1199‐1205.
    1. Beck LH, Bonegio RGB, Lambeau G, et al. M‐type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11‐21.
    1. Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12:983‐997.
    1. Tomas NM, Beck LH Jr, Meyer‐Schwesinger C, et al. Thrombospondin type‐1 domain‐containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277‐2287.

Publication types

LinkOut - more resources